Cyrus Biotechnology is a Seattle-based computational protein design company that engineers biologics from natural proteins for therapeutic indications.
Director of Discovery Dr. Erik Procko recently performed a presentation on Cyrus’ novel IgG-degrading IdeS enzyme development candidates at PepTalk Conference
Cyrus Bio is a computationally-driven discovery company focused on naturally existing proteins that show the potential to be turned into superior therapeutics
Cyrus Biotechnology selects CYR212 as a clinical development candidate for chronic IgG-driven autoimmune disease, including myasthenia gravis and immune thrombocytopenia. The company describes CYR212 as an engineered, next-generation IgG protease with reduced immunogenicity and an extended half-life.
Cyrus Biotechnology reports potent in vivo redosability of an engineered IdeS protease for IgG-driven autoimmune disease, with no anti-drug antibodies. The announcement describes these findings in the context of developing a treatment for the disease.
